Email response from Andy :
The Seabees had an appropriate saying, “The impossible we do right away; miracles take a little longer.”
We have 8 outstanding products, tens of thousands of pain-free customers a pipeline of new innovative products, sound and published clinical research, 8 outstanding employees, solid partners in the Greenwood Group and our distributors, tens of thousands of persevering shareholders, worldwide market clearances, ISO certification, and a very bright future.
1. Have you had any communication with the FDA in the last 3 weeks?
No
2. Which sales/ distribution group is handling the Canada / UK retail launch?
The Greenwood Group is responsible for all of our retail sales operations. It has been going slower than any of us would like but they have just brought in a key (former CEO of a very successful OTC company) executive to move things along. They are doing an outstanding job and we will see dramatic results.
3. You mentioned that Dr. Scholls is now owned by Reckitt Benckiser, and they are too slow to wait. Does this mean that Dr. Scholls testing is dead and there are no more communications with of them?
Instead of waiting for Reckitt Benckiser, we have put Smart Insole™ in the ActiPatch® product line. We have added a $10.00 premium on the retail price and have had very good response from users and distributors.
4. It certainly appears that it is FDA or bust. How long can you keep this ship afloat waiting for the FDA to render its decision?
Only if you think we are just plain stupid, attached is our sales and marketing Power Point Presentation. The US is only 30% of the market.
5. Do you have any marketing campaigns planned or are you cutting back on expenses to focus on post FDA decision launch?
6. Is there anything we as investors can do to assist Bioelectronics Corp. while we await the FDA?
Yes, sell the product, North Americans can buy the products at www.ActiPatch.ca.
